7 results about "Insulin-like growth factor" patented technology

The invention provides AI systems that output proposed combinations of agents such as active pharmaceutical ingredients and other agents useful for a therapeutic objectives. Systems of the invention propose cocktails of those agents and optionally simulate or model effects of those agents to evaluate the potential effects of those agents in accomplishing the therapeutic objective. Specific embodiments provide a skin care composition from the AI system. The composition includes (i) a mixture of agents that includes epidermal growth factor (EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF-1) and one or more of: a collagen-stimulating peptide, a booster of nicotinamide phospho-ribosyl-transferase (NAMPT) expression, coenzyme Q10, a nucleic acid repair enzyme, and a ceramide; (ii) one or more liposomes encapsulating at least a portion of the mixture of agents; and (iii) a moisturizer carrying the liposomes and the mixture of agents.

The application discloses an amplification culture medium and a culture method of human adult epidermal stem cells, and relates to the technical field of stem cell in-vitro culture. The culture medium comprises the following components: fibroblast growth factor, interleukin-6, insulin-like growth factor-1, epidermal growth factor, insulin, growth hormone, hydrocortisone, Y-27632, A83-01, Forsklin, PY60, CHIR99021, linoleic acid, linolenic acid, alanine, asparagine, glutamic acid, glycine, proline, serine, arginine, N-acetyl-L-cysteine, beta-mercaptoethanol and CaCl2. The culture medium can continuously and stably culture human adult epidermal stem cells for more than 20 generations, and a more stable long-term in-vitro amplification system of epidermal stem cells is established. After continuous subculture, the epidermal stem cells can maintain a high proliferation rate and multiple differentiation potential, and have the ability to construct multilayer skin.

This invention provides a mesenchymal stem cell culture medium, its preparation method, and its application. The mesenchymal stem cell culture medium of this invention includes a basal culture medium and functional additives. The functional additives include: recombinant human albumin, recombinant transferrin, recombinant bone morphogenetic protein; recombinant insulin or insulin-like growth factor, recombinant fibroblast growth factor, recombinant epidermal growth factor, recombinant platelet-derived growth factor; thyroid hormones, ethanolamine, carnitine, glucocorticoid regulators, retinoic acid compounds; heparin sodium, signal-regulating lipids, cholesterol, DL-α-tocopherol acetate, linolenic acid, oleic acid, stearic acid; prolactin F68, and Tween 80. The mesenchymal stem cell culture medium of this invention does not contain immunogenic proteins or blood products derived from animals or humans. All components can be supplied with GMP-compliant raw materials and the process can be controlled, ensuring the controllability, safety, and reproducibility of the culture process.

The invention discloses a breast milk oligosaccharide composition for promoting hair growth and application of the breast milk oligosaccharide composition, and belongs to the technical field of hair loss prevention. The breast milk oligosaccharide composition comprises 2 '-fucosyllactose, milk N-tetrasaccharide and 6'-sialic acid lactose in a mass ratio of 2: 1: 1, and further comprises biotin. The composition systematically improves the levels of insulin-like growth factors 1 and vascular endothelial growth factors in serum through oral administration and the like, synergistically regulates the intestinal axis and improves the local microenvironment of hair follicles, so that the hair follicles are effectively promoted to enter and maintain the growth period, and the hair density and diameter are increased. The composition can be applied to medicines, health functional foods and daily chemical products, and is used for preventing or treating alopecia.

The application provides a prostate cancer organoid special culture medium and a culture method thereof, and belongs to the technical field of biological medicine. The prostate cancer organoid special culture medium is composed of a basic culture medium and a culture additive. The basic culture medium does not contain exogenous added Noggin recombinant protein and R-spondin recombinant protein. The culture additive comprises basic fibroblast growth factor, keratinocyte growth factor, fibroblast growth factor 10, insulin, p38MAPK signal pathway inhibitor, insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, forskolin and androgen. The prostate cancer organoid special culture medium can reduce the cost and improve the culture success rate.

This application relates to the biomedical field and discloses the use of hypothalamic paternal IGF2 as a biomarker in the preparation of products for screening and preventing precocious puberty. Specifically, it discloses the application of reagents for detecting the gene imprinting status and / or expression level of hypothalamic paternal insulin-like growth factor 2 in the preparation of precocious puberty screening products, and the application of substances that inhibit the activation of hypothalamic paternal insulin-like growth factor 2 or reduce its expression level in the preparation of drugs for preventing and treating precocious puberty. This application establishes a link between paternal IGF2 and BPA and high-nutrition-induced precocious puberty for the first time, clarifying its core role in mediating the occurrence of precocious puberty and its early warning value, breaking through the limitations of traditional precocious puberty mechanism research. The proposed intervention program is both specific and practical. Among them, the application of Dabu Yin Wan (a traditional Chinese medicine formula) achieves precise targeting of traditional Chinese medicine in the intervention of precocious puberty, and compared with existing intervention technologies, it has significant advantages such as fewer side effects, strong targeting, and high operability.

Methods are provided for determining the amount of an IGF-I protein in a sample using high resolution / high accuracy mass spectrometry. The methods generally include enriching the IGF-I protein in a sample, ionizing the IGF-I protein to generate one or more IGF-I ions, and determining the amount of the IGF-I ions with high resolution / high accuracy mass spectrometry.